← Back to Search

Electrocorticography for Brain Tumor

N/A
Recruiting
Led By Sujit S Prabhu
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients aged 18 years and above
Patients undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed as well as recurrent primary or metastatic brain tumor located in or adjacent to motor and/or speech brain areas
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how well a larger than standard mapping grid works in identifying functional areas of the brain during surgery in patients with brain tumors.

Who is the study for?
This trial is for adults with new or recurring primary or metastatic brain tumors near motor/speech areas, who are undergoing tumor resection at the University of Texas M. D. Anderson Cancer Center. Participants must be able to perform tasks during awake surgery and have signed consent. Those with significant upper limb or speech deficits, impaired vision/hearing affecting study participation are excluded.
What is being tested?
The trial tests electrocorticography (ECoG) using a standard or high-definition grid to map active brain regions during surgery in patients with brain tumors. It aims to improve identification of functional areas related to limb movement and speech.
What are the potential side effects?
As this is a diagnostic procedure rather than a drug treatment, side effects may include typical surgical risks such as infection, bleeding, and potential neurological changes due to the mapping process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am having surgery at M.D. Anderson for a brain tumor near speech or motor areas.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Electrocorticogram (ECoG)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (electrocorticography)Experimental Treatment2 Interventions
Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,067 Previous Clinical Trials
1,802,571 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,927 Previous Clinical Trials
41,017,930 Total Patients Enrolled
University of HoustonOTHER
150 Previous Clinical Trials
47,850 Total Patients Enrolled

Media Library

Direct Electrocortical Stimulation Clinical Trial Eligibility Overview. Trial Name: NCT02754544 — N/A
Brain Tumor Research Study Groups: Diagnostic (electrocorticography)
Brain Tumor Clinical Trial 2023: Direct Electrocortical Stimulation Highlights & Side Effects. Trial Name: NCT02754544 — N/A
Direct Electrocortical Stimulation 2023 Treatment Timeline for Medical Study. Trial Name: NCT02754544 — N/A
~15 spots leftby Jan 2027